Castle Biosciences, Inc. (CSTL)
| Market Cap | 771.04M |
| Revenue (ttm) | 311.88M |
| Net Income (ttm) | 6.08M |
| Shares Out | 28.01M |
| EPS (ttm) | 0.21 |
| PE Ratio | 130.87 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 368,127 |
| Open | 26.58 |
| Previous Close | 27.09 |
| Day's Range | 26.58 - 27.97 |
| 52-Week Range | 16.97 - 35.84 |
| Beta | 0.89 |
| Analysts | Strong Buy |
| Price Target | 39.67 (+44.1%) |
| Earnings Date | Nov 4, 2024 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with d... [Read more]
Financial Performance
In 2023, Castle Biosciences's revenue was $219.79 million, an increase of 60.38% compared to the previous year's $137.04 million. Losses were -$57.47 million, -14.41% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $39.67, which is an increase of 44.10% from the latest price.
News
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employee...
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Meta-analysis concludes DecisionDx-Melanoma provides improved risk stratification over staging alone to inform personalized management of melanoma.
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's executive management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Dec. 4, 2024, ...
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle has been named a Houston Top Workplace by the Houston Chronicle for the 4th straight year and has earned 3 national Culture Exc...
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP24--Castle will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the ASDP 61st Annual Mee...
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's TissueCypher Barrett's Esophagus test surpassed 25,000 test reports delivered since the Company acquired the test at the end ...
Use of Castle Biosciences' DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--New data demonstrates Castle's DecisionDx-Melanoma test can accurately identify patients with a low risk of metastasis who can safely forgo SLNB.
Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, Presi...
Castle Biosciences Reports Third Quarter 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial...
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACG2024--New data at ACG 2024 demonstrates ability of TissueCypher to significantly reduce healthcare costs associated with management of Barrett's esoph...
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces that its executive management is scheduled to present a company overview at three investor conferences in November.
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle will share new data at ASDS supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests.
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of two recent studies that provide further support for the clinical need of its MyPath® Melanoma GEP test.
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday,...
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the OHSU Dept of Dermatology, being held ...
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences' DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #2024SMRCongress--Castle will present new data on DecisionDx-Melanoma and DecisionDx-UM at the 21st International Congress of the Society for Melanoma Res...
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--The company will hold a groundbreaking ceremony Oct. 22 to celebrate the recent construction start of its new corporate campus and off...
New Data at ASTRO 2024 Shows Castle Biosciences' DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASTRO--Castle will share data at ASTRO24 showing its DecisionDx-SCC test can provide impactful risk stratification in high-risk SCC patient sub-populatio...
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences' TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett's Esophagus
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AFS2024--Castle to share data at AFS 2024 showing TissueCypher independently predicts risk of progression to esophageal cancer in Barrett's esophagus pat...
Castle Biosciences' Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
PHOENIX & FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #COO--Castle Biosciences' COO, Kristen Oelschlager, R.N., has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year by AZBio...
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--New study supports ability of DecisionDx-Melanoma to predict SLN positivity risk to help improve patient selection for sentinel lymph node biopsies...
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a new study further supporting use of its DecisionDx-SCC test in guiding decision-making related to the use of radiation therapy.
Castle Biosciences: Inflection Into Profitability
Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitabi...
Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - Founder, President...
Castle Biosciences Reports Second Quarter 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2024.